Ono Pharmaceutical Company, Ltd.
107 articles about Ono Pharmaceutical Company, Ltd.
-
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders
3/14/2024
Sibylla Biotech announced a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System disorders.
-
ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University
3/11/2024
Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.
-
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets
2/21/2024
Ono Pharmaceutical Co., Ltd. announced that it has entered into a research collaboration agreement with InveniAI® LLC, to identify novel therapeutic targets by leveraging cutting-edge InveniAI's artificial intelligence and machine learning.
-
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
2/14/2024
Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.
-
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
2/14/2024
Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
-
Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X
1/9/2024
Ono Pharmaceutical Co., Ltd. informed that it has started a new collaboration with BioMed X on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.
-
Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV's AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs
12/22/2023
Ono Pharmaceutical Co., Ltd. announced that it has entered into a discovery collaboration agreement with EVQLV, INC, to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.
-
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
12/19/2023
BioMed X announced a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan.
-
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
12/1/2023
Ono Pharmaceutical Co., Ltd. announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P., which was established as a corporate venture capital fund in CA, USA in May 2020.
-
Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets
10/24/2023
Turbine, a computational biology company that deploys empirically validated in silico cell simulations to guide biopharma R&D, announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd to identify and validate novel targets within one of Ono’s priority domains of cancer biology.
-
Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field
9/27/2023
Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the oncology field.
-
Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
8/31/2023
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. to discover and develop novel antibodies for the treatment of autoimmune diseases.
-
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
5/16/2023
Personalis, Inc., National Cancer Center, and Ono Pharmaceutical Co., Ltd. announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.
-
ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs
4/18/2023
ONO PHARMA USA announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco, to award each organization one Golden Ticket for an innovative life sciences startup company.
-
ONO PHARMA USA's Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma
3/23/2023
ONO PHARMA USA, INC., announced that its candidate, tirabrutinib, a Bruton's tyrosine kinase inhibitor, was granted Orphan Drug Designation on March 21, 2023 by the U.S. Food and Drug Administration for the treatment of patients with primary central nervous system lymphoma.
-
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
3/23/2023
Macomics Ltd announces that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
-
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
2/22/2023
Cue Biopharma, Inc. (Nasdaq: CUE) announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein designed to induce and expand regulatory T cells (Tregs) for the treatment of autoimmune and inflammatory diseases.
-
KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics® Platform Technology
1/25/2023
KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics ® Platform Technology.
-
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
1/19/2023
Repare Therapeutics Inc. today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”).
-
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
12/14/2022
PrecisionLife Limited, a global techbio company generating the deepest insights into disease biology to create novel precision medicines in chronic diseases announced that it has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd., an R&D-orientated pharmaceutical company.